BioSpace News Archive

Centessa Pharmaceuticals plc, announced that new data from an additional 18-months of continued treatment with SerpinPC from the open-label extension of AP-0101, a Phase 2a study of SerpinPC for the treatment of hemophilia, has been accepted for oral presentation at the 64th American Society of Hematology Annual Meeting, to be held in New Orleans, LA, from December 10 - 13, 2022.

Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present updated data from its Phase 1 UNIVERSAL trial of ALLO-715, an anti-BCMA AlloCAR T product candidate for relapsed/refractory multiple myeloma, in a poster presentation at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place December 10-13, 2022 in New Orleans, LA.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced it will present data from a study on INGREZZA® (valbenazine) capsules evaluating in vitro dissolution performance of whole intact or crushed capsule contents in 40 mg and 80 mg strength.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced that preclinical data from its P-FVIII-101 program, partnered with Takeda, has been selected for an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, being held in New Orleans and virtually December 10–13, 2022.

Poseida Therapeutics, Inc. announced the acceptance of two poster presentations at the European Society for Medical Oncology Immuno-Oncology 2022 Annual Congress, taking place in Geneva, Switzerland and online from December 7-9, 2022.

Grifols (MCE: GRF) (MCE:GRF.P) (NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced that its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S. to screen for genetic risk of alpha1-antitrypsin deficiency (alpha-1), has been cleared by the U.S. Food and Drug Administration (FDA).

Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will present new data in acute lymphoblastic leukemia and acute myeloid leukemia at the 64th Annual Meeting of the American Society of Hematology taking place December 10–13, 2022.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in patients with nucleophosmin (NPM1) mutant and mixed lineage leukemia rearranged (MLLr) relapsed/refractory (R/R) acute leukemias.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new data across its hematology pipeline will be highlighted in 17 presentations at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13 in New Orleans, LA.

Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced that five abstracts related to several of its hematology programs have been accepted for poster presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition.